1,002 Shares in BeOne Medicines Ltd. - Sponsored ADR $ONC Bought by IFP Advisors Inc

Key Points

• IFP Advisors Inc acquired 1,002 shares of BeOne Medicines Ltd. during the second quarter, estimated at a value of approximately $243,000.
• BeOne Medicines reported a quarterly earnings per share of $0.84, exceeding analysts' estimates of $0.48, with revenue of $1.32 billion.
• Several brokerages have upgraded their ratings on BeOne Medicines, with JPMorgan Chase & Co. raising their price target from $345.00 to $385.00 and issuing an "overweight" rating.

IFP Advisors Inc purchased a new position in shares of BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 1,002 shares of the company's stock, valued at approximately $243,000.

A number of other institutional investors have also modified their holdings of ONC. Farther Finance Advisors LLC purchased a new stake in shares of BeOne Medicines in the second quarter worth about $39,000. Signaturefd LLC acquired a new position in BeOne Medicines in the second quarter valued at approximately $49,000. Parallel Advisors LLC acquired a new position in BeOne Medicines in the second quarter valued at approximately $59,000. Avanza Fonder AB purchased a new stake in BeOne Medicines in the 2nd quarter worth approximately $199,000. Finally, Aaron Wealth Advisors LLC acquired a new stake in shares of BeOne Medicines during the 2nd quarter worth approximately $200,000. Hedge funds and other institutional investors own 48.55% of the company's stock.

BeOne Medicines Price Performance

NASDAQ:ONC opened at $318.02 on Friday. The stock has a 50 day moving average of $323.90 and a two-hundred day moving average of $278.16. BeOne Medicines Ltd. - Sponsored ADR has a 12 month low of $170.99 and a 12 month high of $355.30. The firm has a market cap of $34.85 billion, a P/E ratio of -183.83 and a beta of 0.31. The company has a current ratio of 1.95, a quick ratio of 1.72 and a debt-to-equity ratio of 0.04.

BeOne Medicines (NASDAQ:ONC - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported $0.84 earnings per share for the quarter, topping analysts' consensus estimates of $0.48 by $0.36. The firm had revenue of $1.32 billion for the quarter, compared to analyst estimates of $1.24 billion. BeOne Medicines had a negative net margin of 3.89% and a negative return on equity of 1.22%. On average, analysts expect that BeOne Medicines Ltd. - Sponsored ADR will post -5.82 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on ONC. JPMorgan Chase & Co. increased their price target on shares of BeOne Medicines from $345.00 to $385.00 and gave the stock an "overweight" rating in a report on Wednesday, October 8th. Morgan Stanley increased their target price on shares of BeOne Medicines from $313.00 to $330.00 and gave the stock an "overweight" rating in a research note on Friday, June 27th. Zacks Research upgraded BeOne Medicines from a "hold" rating to a "strong-buy" rating in a research note on Thursday, September 18th. Wall Street Zen raised BeOne Medicines from a "buy" rating to a "strong-buy" rating in a report on Friday, October 3rd. Finally, Royal Bank Of Canada raised their price objective on BeOne Medicines from $349.00 to $364.00 and gave the company an "outperform" rating in a report on Thursday, August 7th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $340.30.

Insider Transactions at BeOne Medicines

In other BeOne Medicines news, Director Corazon (Corsee) D. Sanders sold 2,665 shares of the firm's stock in a transaction on Friday, September 5th. The stock was sold at an average price of $337.00, for a total value of $898,105.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Chan Henry Lee sold 10,671 shares of the company's stock in a transaction dated Wednesday, October 8th. The shares were sold at an average price of $350.40, for a total transaction of $3,739,118.40. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 163,484 shares of company stock valued at $51,324,146. 6.62% of the stock is currently owned by company insiders.

BeOne Medicines Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.